-
Our passion
is for lifeAt SynOx, we understand the power of being in control of your own journey in the treatment of your disease. By connecting our industry-leading knowledge and experience with passion and dedication, we aim to provide life-improving options to address the unmet clinical needs of people living with tenosynovial giant cell tumours (TGCT) and other macrophage mediated diseases.
-
Defined
by the journeyAt SynOx, we understand the power of being in control of your own journey in the treatment of your disease. By connecting our industry-leading knowledge and experience with passion and dedication, we aim to provide life-improving options to address the unmet clinical needs of people living with tenosynovial giant cell tumours (TGCT) and other macrophage mediated diseases.
-
Driven
to deliverAt SynOx, we understand the power of being in control of your own journey in the treatment of your disease. By connecting our industry-leading knowledge and experience with passion and dedication, we aim to provide life-improving options to address the unmet clinical needs of people living with tenosynovial giant cell tumours (TGCT) and other macrophage mediated diseases.
-
Life connects us
At SynOx, we understand the power of being in control of your own journey in the treatment of your disease. By connecting our industry-leading knowledge and experience with passion and dedication, we aim to provide life-improving options to address the unmet clinical needs of people living with tenosynovial giant cell tumours (TGCT) and other macrophage mediated diseases.
SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies.
© SynOx Therapeutics. Last Revised: July 2022.